Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Autor: P. Pockros, Ira M. Jacobson, A. M. Di Bisceglie, Gregory T. Everson, Mark E. Mailliard, J.R. Spivey, H.E. Vargas, Thomas G. Stewart, C.A. Kerr, K.R. Reddy, H.A. Elbeshbeshy, Gyongyi Szabo, M.S. Sulkowski, Norah A. Terrault, Nezam H. Afdhal, P. Kwo, K. Rajender Reddy, T.N. Hawkins, Coleman Smith, Eugene R. Schiff, J. Lim, I.M. Jacobson, G. Morelli, Michael W. Fried, Lynn M. Frazier, Andrew J. Muir, Mohamed Hassan, Jordan J. Feld, Giuseppe Morelli, Federico Hinestrosa, Hugo E. Vargas, Mitchell L. Shiffman, Richard K. Sterling, Adrian M. Di Bisceglie, Imtiaz Alam, Nancy Reau, Ziv Ben-Ari, Mark S. Sulkowski, A. Williams, R.T. Chung, J. Darling, C. Trautwein, Josh Levitsky, Stefan Zeuzem, Jonathan M. Fenkel, J. Bredfeldt, Rolland C. Dickson, Kenneth E. Sherman, Ananthakrishnan Ramani, R.S. Brown, Jama M. Darling, M.W. Fried, A. Kuo, David R. Nelson, Joseph S. Galati, Jacqueline G. O'Leary, W. Harlan, D. Nelson, Joseph K. Lim, A.S. Lok, Michael P. Manns, Alexander Kuo, Robert S. Brown, Brian L. Pearlman, K. Watts, S.C. Gordon

Publikováno v: Gastroenterology. 150(2)

Background & Aims The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evalua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0386631f32a4d6005c94cae77bb5183
https://pubmed.ncbi.nlm.nih.gov/26497081

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.